Moderna skyrockets 16% to record high after FDA clears coronavirus vaccine for phase 2 study | ||
Thursday, 7 May 2020 ()
 · *Moderna stock surged as much as 16% early Thursday after the company announced its coronavirus vaccine candidate received FDA approval for phase 2 trials.*· *The biotech firm is preparing for a phase 3 study to begin in the early summer with the goal of marketing the drug as early as 2021, according to a Thursday... |